Clinical trial · Interventional
A Study of LY3435151 in Participants With Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
NCT04099277CI-TRIAL-00053590terminatedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated due to strategic business decision by Eli Lilly and Company.
Summary
Brief summary (as posted)
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Carcinoma | Cervical Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| High Grade Serous Ovarian Carcinoma | — | UNRESOLVED | — |
| Leiomyosarcoma | Leiomyosarcoma | ONTOLOGY_EXACT | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Triple-negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
| Undifferentiated Pleomorphic Sarcoma | Undifferentiated Pleomorphic Sarcoma |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY3435151 | Drug | — | UNRESOLVED |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Part A: 10 milligrams (mg) LY3435151
- description
- Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
- interventionNames
- Drug: LY3435151
- type
- EXPERIMENTAL
- label
- Part B: LY3435151 + Pembrolizumab Dose Escalation
- description
- Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
- interventionNames
- Drug: LY3435151
- Drug: Pembrolizumab
- type
- EXPERIMENTAL
- label
- Part C: LY3435151 Dose Expansion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant must have certain types of cancer, which your study doctor will discuss with you * Participant must have stopped other forms of treatment for cancer, which your study doctor will discuss with you * Participant must be able and willing to provide a sample of your tumor before beginning treatment and once while on treatment. For certain tumor types, the outcome of the biopsy may exclude you from the study treatment (for Phase 1b) * Participant must agree to use birth control * Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you Exclusion Criteria: * Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled hepatitis B or C virus infection * Participant must not have an autoimmune disease, which your study doctor will discuss with you * Participant must not use corticosteroids, which your study doctor will discuss with you * Participant must not have heart disease, Crohn's disease or brain cancer * Participant must not be pregnant or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.